盤中異動 | 小鵬汽車漲超10%,機構指23年銷量和盈利能力料進一步高增長
智通財經APP獲悉,$小鵬汽車-W(09868.HK)$早盤強勢上漲,現漲超10%,成交額近3億港元。隔夜美股$小鵬汽車(XPEV.US)$飆升超13%。
日前,小鵬汽車披露數據顯示,12月交付11292輛,同環比分別-29.43%/+94.32%。小鵬G9交付4020輛,環比+160%。2022年全年小鵬累計交付12.08萬輛,同比+23%。東吳證券點評稱,23年,小鵬汽車還將推出兩款全新車型,新品週期強勁,推動銷量和盈利能力進一步高增長。稍早,招商證券表示,公司重磅車型G9已開啓規模交付,2023年1月明顯放量。隨着G9銷量回升,及23年換代車型推出,基本面有望逐步邊際改善。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.